Cencora, Inc. $COR Shares Sold by Kepler Cheuvreux Suisse SA

Kepler Cheuvreux Suisse SA trimmed its stake in Cencora, Inc. (NYSE:COR) by 11.0% during the first quarter, Holdings Channel.com reports. The fund owned 25,749 shares of the company’s stock after selling 3,175 shares during the period. Kepler Cheuvreux Suisse SA’s holdings in Cencora were worth $8,089,000 at the end of the most recent quarter.

Several other large investors have also recently made changes to their positions in COR. Kemnay Advisory Services Inc. purchased a new position in shares of Cencora during the 4th quarter worth approximately $25,000. Oakworth Capital Inc. purchased a new stake in Cencora in the fourth quarter valued at approximately $26,000. Elyxium Wealth LLC purchased a new stake in Cencora in the fourth quarter valued at approximately $27,000. Archer Investment Corp lifted its stake in Cencora by 134.3% during the fourth quarter. Archer Investment Corp now owns 82 shares of the company’s stock worth $28,000 after purchasing an additional 47 shares in the last quarter. Finally, Motiv8 Investments LLC purchased a new position in shares of Cencora during the fourth quarter worth $29,000. 97.52% of the stock is currently owned by institutional investors and hedge funds.

Cencora Stock Performance

NYSE:COR opened at $296.43 on Friday. Cencora, Inc. has a 52 week low of $244.82 and a 52 week high of $377.54. The company has a fifty day simple moving average of $277.91 and a two-hundred day simple moving average of $320.37. The company has a quick ratio of 0.59, a current ratio of 0.95 and a debt-to-equity ratio of 3.40. The company has a market cap of $57.67 billion, a price-to-earnings ratio of 22.73, a price-to-earnings-growth ratio of 1.65 and a beta of 0.58.

Cencora (NYSE:COR) last announced its quarterly earnings data on Wednesday, May 6th. The company reported $4.75 earnings per share (EPS) for the quarter, missing the consensus estimate of $4.82 by ($0.07). The company had revenue of $78.36 billion during the quarter, compared to analyst estimates of $81.09 billion. Cencora had a net margin of 0.78% and a return on equity of 135.20%. The firm’s revenue was up 3.9% on a year-over-year basis. During the same quarter in the previous year, the business posted $4.42 earnings per share. Cencora has set its FY 2026 guidance at 17.650-17.900 EPS. As a group, equities analysts anticipate that Cencora, Inc. will post 17.79 earnings per share for the current fiscal year.

Cencora declared that its board has approved a stock repurchase program on Thursday, May 21st that permits the company to buyback $2.00 billion in shares. This buyback authorization permits the company to reacquire up to 3.9% of its stock through open market purchases. Stock buyback programs are often a sign that the company’s leadership believes its stock is undervalued.

Cencora Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Monday, June 1st. Shareholders of record on Friday, May 15th were given a $0.60 dividend. The ex-dividend date of this dividend was Friday, May 15th. This represents a $2.40 dividend on an annualized basis and a yield of 0.8%. Cencora’s dividend payout ratio (DPR) is currently 18.40%.

Insider Activity

In related news, Director Lauren M. Tyler acquired 550 shares of the stock in a transaction dated Monday, June 22nd. The stock was acquired at an average cost of $270.23 per share, with a total value of $148,626.50. Following the completion of the transaction, the director owned 4,359 shares in the company, valued at $1,177,932.57. This represents a 14.44% increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Insiders own 0.38% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on COR shares. UBS Group lifted their price objective on Cencora from $410.00 to $412.00 and gave the company a “buy” rating in a research note on Thursday, May 7th. William Blair assumed coverage on Cencora in a report on Tuesday, April 28th. They set a “market perform” rating for the company. Bank of America raised their target price on Cencora from $280.00 to $285.00 and gave the company a “neutral” rating in a report on Wednesday, June 24th. Wells Fargo & Company dropped their target price on Cencora from $429.00 to $331.00 and set an “overweight” rating for the company in a research report on Monday, May 11th. Finally, Citigroup cut their price target on shares of Cencora from $405.00 to $355.00 and set a “buy” rating on the stock in a research note on Thursday, May 7th. Eleven analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $367.75.

About Cencora

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.